Small studies suggest the drugs help people with MS lose weight without raising disease activity, but the review flags muscle loss and NAION eye risk.
Recap by typeshit. Full story at BIOENGINEER.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Her talk at the Indonesian congress compared tirzepatide's clinical trial results with what doctors see in real-world practice.
Bhekisisa points out that local treatment guidelines now recommend GLP-1s for obesity, while the price keeps them out of reach for many.
Loading…